APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease
AuthorLim, YY; Villemagne, VL; Laws, SM; Pietrzak, RH; Snyder, PJ; Ames, D; Ellis, KA; Harrington, K; Rembach, A; Martins, RN; ...
Source TitleMolecular Psychiatry
PublisherNATURE PUBLISHING GROUP
University of Melbourne Author/sMasters, Colin; Ames, David; Rowe, Christopher; Villemagne, Victor; REMBACH, ALAN; Ellis, Kathryn; Lim, Yen Ying; Maruff, Paul; Harrington, Karra
AffiliationFlorey Department of Neuroscience and Mental Health
Medicine and Radiology
Anatomy and Neuroscience
Business & Economics
Document TypeJournal Article
CitationsLim, Y. Y., Villemagne, V. L., Laws, S. M., Pietrzak, R. H., Snyder, P. J., Ames, D., Ellis, K. A., Harrington, K., Rembach, A., Martins, R. N., Rowe, C. C., Masters, C. L. & Maruff, P. (2015). APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. MOLECULAR PSYCHIATRY, 20 (11), pp.1322-1328. https://doi.org/10.1038/mp.2014.123.
Access StatusOpen Access
Accumulation of β-amyloid (Aβ) in the brain is associated with memory decline in healthy individuals as a prelude to Alzheimer's disease (AD). Genetic factors may moderate this decline. We examined the role of apolipoprotein E (ɛ4 carrier[ɛ4(+)], ɛ4 non-carrier[ɛ4(-)]) and brain-derived neurotrophic factor (BDNF(Val/Val), BDNF(Met)) in the extent to which they moderate Aβ-related memory decline. Healthy adults (n=333, Mage=70 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent Aβ neuroimaging. Neuropsychological assessments were conducted at baseline, 18-, 36- and 54-month follow-ups. Aβ positron emission tomography neuroimaging was used to classify participants as Aβ(-) or Aβ(+). Relative to Aβ(-)ɛ4(-), Aβ(+)ɛ4(+) individuals showed significantly faster rates of cognitive decline over 54 months across all domains (d=0.40-1.22), while Aβ(+)ɛ4(-) individuals showed significantly faster decline only on verbal episodic memory (EM). There were no differences in rates of cognitive change between Aβ(-)ɛ4(-) and Aβ(-)ɛ4(+) groups. Among Aβ(+) individuals, ɛ4(+)/BDNF(Met) participants showed a significantly faster rate of decline on verbal and visual EM, and language over 54 months compared with ɛ4(-)/BDNF(Val/Val) participants (d=0.90-1.02). At least two genetic loci affect the rate of Aβ-related cognitive decline. Aβ(+)ɛ4(+)/BDNF(Met) individuals can expect to show clinically significant memory impairment after 3 years, whereas Aβ(+)ɛ4(+)/BDNF(Val/Val) individuals can expect a similar degree of impairment after 10 years. Little decline over 54 months was observed in the Aβ(-) and Aβ(+) ɛ4(-) groups, irrespective of BDNF status. These data raise important prognostic issues in managing preclinical AD, and should be considered in designing secondary preventative clinical trials.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
- Minerva Elements Records 
- Business & Economics Collected Works - Research Publications 
- Anatomy and Neuroscience - Research Publications 
- Medicine and Radiology - Research Publications 
- Psychiatry - Research Publications 
- Florey Department of Neuroscience and Mental Health - Research Publications